State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease
- PMID: 36697295
- DOI: 10.1016/j.blre.2023.101040
State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease
Abstract
Amyloidosis is the term to define a broad array of rare protein misfolding syndromes. Among them, light chain (AL) amyloidosis is the most common, affecting roughly 10 people per million/year. The core purpose of the present literature review is to shed light on the academic and clinical knowledge on the condition, encompassing its i) epidemiology, ii) economic burden, and iii) quality of life consequences. The areas of interest are Europe and North America. Literature search was primarily performed on Embase® and finally integrated with additional, deemed eligible, sources. Pre-defined PICOS criteria were employed for the inclusion and exclusion processes. A total of 64 studies were comprehensively included in the current literature review as compliant with the inclusion criteria. The results were presented according to the outcomes of interest and eventually triangulated and compared to available literature studies. A broad picture on the main aspects of AL amyloidosis is delivered.
Keywords: AL amyloidosis; Epidemiology; Light-chain amyloidosis; PRISMA guidelines; Risk-staging; Systematic literature review.
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest AS and GG are employees of AdRes s.r.l., which have received project funding by Janssen for the development of this review. LP is partner and employee of AdRes s.r.l., which has received project funding by Janssen for the development of this research. SB and AL are employees of Janssen. GP is full professor of clinical chemistry at University of Pavia, his competing interests are: Alexion (Advisory board, honoraria), Argobio (Advisory board, honoraria), Janssen (Advisory board, honoraria), Protego (Advisory board, honoraria), Gate bioscience (Research funding), The Binding Site (Research funding, honoraria), Pfizer (Honoraria), Prothena (Honoraria), Sebia (Honoraria), Siemens (Honoraria).
Similar articles
-
Epidemiology and clinical outcomes of light-chain amyloidosis in Sweden: A nationwide population-based study.Eur J Haematol. 2023 Nov;111(5):697-705. doi: 10.1111/ejh.14063. Epub 2023 Aug 2. Eur J Haematol. 2023. PMID: 37533343
-
Light-chain (AL) amyloidosis for nephrologists-treatment standard.Nephrol Dial Transplant. 2024 Dec 20;40(1):34-47. doi: 10.1093/ndt/gfae224. Nephrol Dial Transplant. 2024. PMID: 39375844 Review.
-
The global epidemiology of acquired factor X deficiency.Hematology. 2025 Dec;30(1):2476254. doi: 10.1080/16078454.2025.2476254. Epub 2025 Mar 27. Hematology. 2025. PMID: 40151020 Review.
-
Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication.Methodist Debakey Cardiovasc J. 2022 Mar 14;18(2):27-35. doi: 10.14797/mdcvj.1070. eCollection 2022. Methodist Debakey Cardiovasc J. 2022. PMID: 35414848 Free PMC article. Review.
-
Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review.JAMA. 2020 Jul 7;324(1):79-89. doi: 10.1001/jama.2020.5493. JAMA. 2020. PMID: 32633805
Cited by
-
Incidence and prevalence of light chain amyloidosis in the United States in 2019-2021 using Optum EHR data.Sci Rep. 2025 Jul 11;15(1):25149. doi: 10.1038/s41598-025-09498-7. Sci Rep. 2025. PMID: 40646057 Free PMC article.
-
Modeling immunoglobulin light chain amyloidosis in Caenorhabditis elegans.Dis Model Mech. 2025 Jul 1;18(7):dmm052230. doi: 10.1242/dmm.052230. Epub 2025 Jul 25. Dis Model Mech. 2025. PMID: 40709584 Free PMC article.
-
Diagnostic pathways, cardiac manifestations and outcomes in light chain amyloidosis: analysis of a US claims database.Open Heart. 2025 Apr 4;12(1):e003124. doi: 10.1136/openhrt-2024-003124. Open Heart. 2025. PMID: 40185502 Free PMC article.
-
Role of the mechanisms for antibody repertoire diversification in monoclonal light chain deposition disorders: when a friend becomes foe.Front Immunol. 2023 Jul 13;14:1203425. doi: 10.3389/fimmu.2023.1203425. eCollection 2023. Front Immunol. 2023. PMID: 37520549 Free PMC article. Review.
-
Amyloidosis-Related Cardiomyopathy Revealing Waldenstrom Macroglobulinemia: A Case Report.Cureus. 2025 Apr 30;17(4):e83278. doi: 10.7759/cureus.83278. eCollection 2025 Apr. Cureus. 2025. PMID: 40453263 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical